Evidence map›Paper›PMID 38188359›Full record

ArticleTherapeutic advances in infectious disease

Screening with urine

Murillo M Cipolat, Débora R R Rodrigues, Letícia G Silveira, Inês G Silveira, Mahara S V Nothaft, Claiton V Brenol, Larissa R da Silva, Alessandro C Pasqualotto, Diego R Falci

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in infectious disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Murillo M CipolatMedical Sciences Graduate Program, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Débora R R RodriguesFaculty of Medical Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Letícia G SilveiraMedical Sciences Graduate Program, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Inês G SilveiraClinical Medicine Department, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil.
Mahara S V NothaftSchool of Medicine, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil.
Claiton V BrenolMedical Sciences Graduate Program, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Larissa R da SilvaMolecular Biology Laboratory, Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil.
Alessandro C PasqualottoMolecular Biology Laboratory, Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil.
Diego R FalciPontif'icia Universidade Catolica do Rio Grande do Sul, Porto Alegre 90619-900, Brazil.ORCID https://orcid.org/0000-0002-8683-3833
Universidade Federal do Rio Grande do Sul · BRPontifícia Universidade Católica do Rio Grande do Sul · BRSanta Casa de Misericórdia de Marília · BRUniversidade Federal de Ciências da Saúde de Porto Alegre · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Histoplasmosis is the second most frequent granulomatous disease in patients treated with tumor necrosis factor (TNF)-α inhibitors, second only to tuberculosis. However, there is limited information about pre-therapy screening procedures and the need for preventive treatments for patients who will start immunobiologicals. Methods: This is a cohort study that evaluated the prevalence of histoplasmosis in asymptomatic HIV-negative patients before initiation of TNF-α inhibitors by testing for Results: From January 2021 to December 2022, 54 patients who were prescribed a TNF-α inhibitor agent for treating autoimmune diseases in centers in southern Brazil were included. In the screening before therapy, the prevalence of a positive urinary Conclusion: The prevalence of

Indexed as

anti-TNF-αbiological drugshistoplasmosisinflammatory bowel diseaserheumatoid arthritisTNF-α inhibitors

Identifiers

PMID38188359
PMCPMC10768624
OpenAlexW4390582179

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.